Characteristic | Uniform distribution (DMVD < 10) (n = 187) | Uneven distribution (DMVD > 10) (68) | Statistics | P |
---|---|---|---|---|
Age (years) | 51.86 ± 9.55 | 52.04 ± 9.84 | -0.138 | 0.890 |
Menopause | 0.389 | 0.572 | ||
Postmenopausal | 88 | 35 | ||
Premenopausal | 99 | 33 | ||
Family history | 0.012 | 1.000 | ||
No | 174 | 63 | ||
Yes | 13 | 5 | ||
Diameter | 2.21 ± 0.95 | 2.67 ± 1.31 | -3.061 | 0.002 |
Quadrant | 5.680 | 0.224 | ||
Areolar | 3 | 2 | ||
Inner upper | 39 | 6 | ||
Inner lower | 17 | 8 | ||
Outer lower | 32 | 11 | ||
Outer upper | 96 | 41 | ||
Patterns of enhancement | 179.854 | 0.000 | ||
Homogeneous | 77(41.2%) | 5(7.4%) | ||
Heterogeneous | 110(58.8%) | 11(16.2%) | ||
Peripheral | 0(0%) | 52(76.5%) | ||
Difference of MVD (Edge - Center) | 1.29 ± 5.03 | 15.60 ± 4.27 | -20.873 | 0.000 |
Histological grade | 2.105 | 0.349 | ||
I | 50 | 13 | ||
II | 120 | 46 | ||
III | 17 | 9 | ||
Cancer thrombosis | 1.891 | 0.204 | ||
Negative | 140 | 45 | ||
Positive | 47 | 23 | ||
Nodal metastasis | 0.174 | 0.777 | ||
Negative | 88 | 30 | ||
Positive | 99 | 38 | ||
Number of metastatic nodes | 2.91 ± 5.97 | 6.21 ± 9.42 | -3.302 | 0.001 |
Clinical stage | 18.458 | 0.002 | ||
I | 46(24.6%) | 13(19.1%) | ||
IIA | 60(32.1%) | 16(23.5%) | ||
IIB | 64(34.2%) | 20(29.4%) | ||
IIIA | 11(5.9%) | 7(10.3%) | ||
IIIB | 2(1.1%) | 5(7.4%) | ||
IIIC | 4(2.1%) | 7(10.3%) | ||
IV | 0(0%) | 0(0%) | ||
ER | 18.731 | 0.000 | ||
Negative | 57(30.5%) | 41(60.3%) | ||
Positive | 130(69.5%) | 27(39.7%) | ||
PgR | 26.314 | 0.000 | ||
Negative | 48(25.7%) | 41(60.3%) | ||
Positive | 139(74.3%) | 27(39.7%) | ||
HER2 | 9.786 | 0.003 | ||
Negative | 167(89.3%) | 50(73.5%) | ||
Positive | 20(10.7%) | 18(26.5%) | ||
Ki67 | 10.827 | 0.001 | ||
Negative (<14%) | 120(64.2%) | 28(41.2%) | ||
Positive (>14%) | 67(35.8%) | 40(58.8%) | ||
P53 (%) | 32.08 ± 31.58 | 29.90 ± 33.94 | 0.479 | 0.633 |
Clinicopathological subtypes | 42.300 | 0.000 | ||
Luminal A | 102(54.5%) | 17(25.0%) | ||
Luminal B (Ki67+) | 44(23.5%) | 8(11.8%) | ||
Luminal B (HER2+) | 14(7.5%) | 8(11.8%) | ||
HER2 overexpression | 6(3.2%) | 10(14.7%) | ||
TNBC | 21(11.2%) | 25(36.8%) | ||
Operation | 0.819 | 0.485 | ||
Mastectomy | 166 | 63 | ||
Tumorectomy | 21 | 5 | ||
Chemotherapy program | 17.357 | 0.004 | ||
Not performed | 0(0%) | 2(2.9%) | ||
CMF | 2(1.1%) | 0(0%) | ||
CAF or AC | 60(32.1%) | 12(17.6%) | ||
CEF or EC | 43(23.0%) | 19(27.9%) | ||
T or TC or TP | 59(31.6%) | 17(25.0%) | ||
TAC or A-T | 23(12.3%) | 18(26.5%) | ||
Radiotherapy | 2.012 | 0.160 | ||
Not performed | 104 | 31 | ||
Performed | 83 | 37 | ||
Endocrine therapy | 38.443 | 0.000 | ||
Not performed | 27(14.4%) | 35(51.5%) | ||
TAM | 99(52.9%) | 20(29.4%) | ||
LHRH | 13(7.0%) | 5(7.4%) | ||
AI | 48(25.7%) | 8(11.8%) | ||
Targeted therapy | 0.116 | 1.000 | ||
Not performed | 183 | 67 | ||
Performed | 4 | 1 | ||
Overall survival | 99.5% | 85.3% | 24.308 | 0.000 |
Event | 1 | 10 | ||
Deaths | 1 | 9 | ||
Lost to Follow-up | 0 | 1 | ||
Median survival time | 54.0 | 54.0 | 14.885 | 0.000 |
Disease-free survival | 99.5% | 67.6% | 62.030 | 0.000 |
Event | 1 | 22 | ||
Local recurrence | 0 | 1 | ||
Contralateral breast cancer | 0 | 4 | ||
Lung metastasis | 0 | 2 | ||
Hepatic metastasis | 0 | 5 | ||
Brain metastasis | 0 | 3 | ||
Multi-organ | 1 | 6 | ||
Lost to Follow-up | 0 | 1 | ||
Disease-free survival | 54.0 | 31.9 | 47.546 | 0.000 |
Follow-up time | 0.384 | 0.701 | ||
Median | 23.0 | 22.0 | ||
Range | 12-58 | 12-59 |